Form 4: GE HealthCare CFO Saccaro Receives Equity Award

GE HealthCare Technologies Inc. Chief Financial Officer James Saccaro was granted 12,475 restricted stock units and 32,797 employee stock options.

Summary

• James Saccaro, Chief Financial Officer of GE HealthCare Technologies Inc. (GEHC), was awarded 12,475 restricted stock units (RSUs) on March 2, 2026.
• Each RSU represents the right to receive one share of GE HealthCare common stock.
• The RSUs will vest in three tranches: 33% on September 2, 2027, 33% on September 2, 2028, and 34% on September 2, 2029.
• Saccaro also received an award of 32,797 employee stock options on March 2, 2026, with an exercise price of $80.16 per share.
• These stock options will become exercisable on the same vesting schedule as the RSUs: 33% on September 2, 2027, 33% on September 2, 2028, and 34% on September 2, 2029.
• The employee stock options have an expiration date of March 2, 2036.
• Following these transactions, Saccaro beneficially owns 84,161 shares of common stock directly and 32,797 employee stock options directly.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development for corporate governance and executive retention, as it aligns the CFO's long-term interests with shareholder value creation, though it is a routine compensation event rather than a direct operational or financial performance indicator.

Positives

• The equity awards align the Chief Financial Officer's long-term financial interests with those of GE HealthCare's shareholders.
• The multi-year vesting schedule for both RSUs and stock options serves as a strong retention incentive for a key executive.
• The awards are a standard component of executive compensation, reflecting confidence in the executive's continued contribution to the company's performance.

Negatives

• The awards do not provide immediate liquidity or cash benefit to the executive, as they are subject to future vesting schedules.
• The value realized from the stock options is dependent on the future appreciation of GE HealthCare's stock price above the exercise price of $80.16.

Risks

• The value of the restricted stock units and stock options is subject to market fluctuations of GE HealthCare's common stock.
• The vesting of these awards is contingent upon the executive's continued employment with the company through the specified vesting dates.
• Future company performance and market conditions could impact the ultimate value of these equity awards.

Future Outlook

The equity awards are designed to incentivize the Chief Financial Officer's long-term performance and commitment to GE HealthCare, with vesting tied to future dates, suggesting an expectation of continued contributions and value creation.

Industry Context

StockSavvy.ai notes that equity awards are a common practice in the healthcare technology sector to incentivize and retain key executives, aligning their interests with long-term company performance and strategic objectives.

Comparison to Industry Standards

• StockSavvy.ai observes that multi-year vesting schedules for executive equity awards, such as the 3-year schedule seen here, are standard practice across the healthcare technology industry, comparable to practices at companies like Siemens Healthineers or Philips.
• The grant of both restricted stock units and stock options is a common dual approach in executive compensation packages, offering both retention value (RSUs) and upside potential (options) tied to stock performance, consistent with peer companies.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential positive impact through enhanced executive alignment with long-term company performance and value creation.
• Employees: No direct impact on general employees, but reflects the company's compensation strategy for key leadership.

Next Steps

• Vesting of 33% of restricted stock units and exercisability of 33% of employee stock options on September 2, 2027.
• Vesting of an additional 33% of restricted stock units and exercisability of an additional 33% of employee stock options on September 2, 2028.
• Vesting of the final 34% of restricted stock units and exercisability of the final 34% of employee stock options on September 2, 2029.

Key Dates

Recommendation

This Form 4 reports a routine equity award to a key executive, which is a standard compensation practice designed to align management interests with long-term shareholder value. It does not provide new information that would fundamentally alter the investment thesis for GE HealthCare Technologies Inc., thus a 'hold' recommendation is maintained.

Keywords

GE HealthCare, GEHC, James Saccaro, CFO, Form 4, Equity Award, Restricted Stock Units, Stock Options, Insider Transaction, Executive Compensation